MD Anderson and Turning Point Therapeutics announce strategic alliance to advance precision cancer therapies
The University of Texas MD Anderson Cancer Center and Turning Point Therapeutics, Inc., today announced a strategic research and development alliance to expand the evaluation of two of Turning Point's investigational small molecules focusing on precision medicine targets well known in oncology.
The initial focus of the alliance will be Turning Point’s lead drug candidate, repotrectinib, a next-generation kinase inhibitor targeting...
MD Anderson, Invectys and CTMC announce strategic collaboration for CAR T cell therapy development
The University of Texas MD Anderson Cancer Center, Invectys, Inc. and the Cell Therapy Manufacturing Center (CTMC), a joint venture between...
Estimating tumor-specific total mRNA level predicts cancer outcomes
Researchers at The University of Texas MD Anderson Cancer Center have developed a new approach to quantify tumor-specific total mRNA levels...
Genetic study offers new insights into DCIS biology, progression
A new study led by the global Cancer Grand Challenges PRECISION team, including researchers from The University of Texas MD Anderson Cancer Center, shifts the long-held belief that all invasive breast cancers following ductal carcinoma in situ (DCIS) arise from the original DCIS lesion. The results, published today in Nature Genetics, demonstrate that roughly one in five invasive cancers were genetically unrelated to the original DCIS...
MD Anderson and Resilience launch joint venture to accelerate development and manufacturing of innovative cell therapies for cancer
The University of Texas MD Anderson Cancer Center and National Resilience, Inc., today announced the launch of a joint venture, the Cell Therapy...
MD Anderson Research Highlights for June 1, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...